company background image
KMDA logo

Kamada NasdaqGS:KMDA Stock Report

Last Price

US$5.35

Market Cap

US$314.2m

7D

-7.0%

1Y

-0.7%

Updated

08 Sep, 2024

Data

Company Financials +

KMDA Stock Overview

Manufactures and sells plasma-derived protein therapeutics.

KMDA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Kamada Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kamada
Historical stock prices
Current Share Price₪5.35
52 Week High₪6.53
52 Week Low₪4.08
Beta0.25
11 Month Change-3.26%
3 Month Change1.90%
1 Year Change-0.74%
33 Year Change0.75%
5 Year Change1.71%
Change since IPO-42.16%

Recent News & Updates

Recent updates

Kamada secures $22M extension of Canadian supply tender

Oct 19

Kamada Q2 2022 Earnings Preview

Aug 16

Kamada inks agreement for the distribution of three biosimilar products in Israel

Jan 13

Kamada Looks Cheap AS Takeda Deal Creates Value

Nov 02

Shareholder Returns

KMDAUS BiotechsUS Market
7D-7.0%-4.0%-4.4%
1Y-0.7%12.4%19.1%

Return vs Industry: KMDA underperformed the US Biotechs industry which returned 12.4% over the past year.

Return vs Market: KMDA underperformed the US Market which returned 19.1% over the past year.

Price Volatility

Is KMDA's price volatile compared to industry and market?
KMDA volatility
KMDA Average Weekly Movement6.3%
Biotechs Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: KMDA has not had significant price volatility in the past 3 months.

Volatility Over Time: KMDA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990378Amir Londonwww.kamada.com

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.

Kamada Ltd. Fundamentals Summary

How do Kamada's earnings and revenue compare to its market cap?
KMDA fundamental statistics
Market capUS$314.22m
Earnings (TTM)US$15.07m
Revenue (TTM)US$154.57m

20.8x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KMDA income statement (TTM)
RevenueUS$154.57m
Cost of RevenueUS$89.66m
Gross ProfitUS$64.92m
Other ExpensesUS$49.85m
EarningsUS$15.07m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.26
Gross Margin42.00%
Net Profit Margin9.75%
Debt/Equity Ratio0%

How did KMDA perform over the long term?

See historical performance and comparison